GlassScriptPhysician profile
Leonard E Kane
NPI 1588653786
$9,835.36
in general payments reported to CMS, 2019-2025
36 companies · $2,112 in 2025
The $2,112 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $800 · 2021: $903 · 2022: $807 · 2023: $1,946 · 2024: $1,928 · 2025: $2,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,882 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,882.33 |
| Education | $104.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,172.26 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,714.15 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $642.63 | 2019-2025 | Stelara, Tremfya, Remicade |
| Genzyme Corporation | $550.20 | 2022-2025 | |
| Pfizer INC. | $460.51 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $443.55 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $441.48 | 2024-2025 | Omvoh |
| Celgene Corporation | $366.30 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $306.49 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $303.31 | 2019-2025 | Ocaliva |
| Fresenius Kabi USA, LLC | $255.88 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Takeda Pharmaceuticals U.S.A., INC. | $231.97 | 2019-2025 | Eohilia, Entyvio |
| Ironwood Pharmaceuticals, INC | $215.26 | 2019-2024 | Linzess |
| Madrigal Pharmaceuticals | $210.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $190.04 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $152.98 | 2024-2025 | Vegzelma, Zymfentra |
| Ardelyx, INC. | $148.54 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $132.64 | 2020-2023 | Sutab |
| Merck Sharp & Dohme LLC | $129.79 | 2019-2023 | Dificid, Zinplava |
| Novo Nordisk INC | $120.02 | 2019-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $115.16 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $92.84 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $69.44 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $54.50 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $45.51 | 2024-2025 | Zenpep |
| Micro-Tech Endoscopy USA, INC. | $35.50 | 2023 | Lesion Hunter, Multi Band Ligator |
| Glaxosmithkline, LLC. | $34.61 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.73 | 2023 | Cyltezo |
| Boston Scientific Corporation | $31.20 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $26.60 | 2025 | |
| Depuy Synthes Sales INC. | $25.87 | 2019-2022 | |
| Organon LLC | $23.93 | 2023 | Renflexis |
| Redhill Biopharma INC. | $20.67 | 2020 | |
| Evoke Pharma, INC. | $15.44 | 2025 | |
| Amarin Pharma, INC. | $14.01 | 2020 | |
| Qol Medical, LLC | $9.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.